Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBIT: 2018-2025

Historic EBIT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$16.5 million.

  • Arcturus Therapeutics Holdings' EBIT fell 53.79% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.3 million, marking a year-over-year increase of 2.73%. This contributed to the annual value of -$95.7 million for FY2024, which is 22.33% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' EBIT stood at -$16.5 million, which was down 42.15% from -$11.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year EBIT high stood at $121.5 million for Q4 2022, and its period low was -$57.7 million during Q1 2021.
  • Its 3-year average for EBIT is -$19.9 million, with a median of -$18.3 million in 2023.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' EBIT tumbled by 509.45% in 2021 and then surged by 422.62% in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' EBIT stood at -$37.6 million in 2021, then skyrocketed by 422.62% to $121.5 million in 2022, then slumped by 115.04% to -$18.3 million in 2023, then tumbled by 82.76% to -$33.4 million in 2024, then slumped by 53.79% to -$16.5 million in 2025.
  • Its EBIT was -$16.5 million in Q3 2025, compared to -$11.6 million in Q2 2025 and -$16.8 million in Q1 2025.